The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (original) (raw)

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two diseases that form a broad neurodegenerative continuum. Considerable effort has been made to unravel the genetics of these disorders, and, based on this work, it is now clear that ALS and FTD have a significant genetic overlap. TARDBP, SQSTM1, VCP, FUS, TBK1, CHCHD10, and most importantly C9orf72, are the critical genetic players in these neurological disorders. Discoveries of these genes have implicated autophagy, RNA regulation, and vesicle and inclusion formation as the central pathways involved in neurodegeneration. Here we provide a summary of the significant genes identified in these two intrinsically linked neurodegenerative diseases and highlight the genetic and pathological overlaps.

Keywords: amyotrophic lateral sclerosis, frontotemporal dementia, neurological disorders, neurodegeneration, overlapping genetics

Introduction

Amyotrophic lateral sclerosis (ALS, OMIM #105400) is a fatal neurological disorder affecting motor neurons located in the frontal cortex, brainstem, and spinal cord (Cleveland and Rothstein, 2001). The disease typically begins as muscle weakness in a limb, or occasionally with changes in voice or difficulty swallowing, which progresses to generalized weakness and paralysis of respiratory muscles leading to death due to respiratory failure. Approximately 10% of all ALS cases have a family history of the disease, while the remaining 90% are sporadic. The incidence of ALS is estimated to be 2.1 new cases per 100,000 population per year (Chio et al., 2013), and approximately 6,000 people are newly diagnosed with ALS each year in the United States alone. The number of ALS cases around the world is increasing due to the aging of the global population (Arthur et al., 2016). There are currently no effective treatments for ALS, except for edaravone, which reduces the decline in daily functioning, and riluzole, which prolongs patients’ survival by a few months (Miller et al., 2012; Rothstein, 2017).

Frontotemporal degeneration (FTD) is one of the most common types of dementia in people under 65. FTD may be divided into three primary subtypes, namely behavioral variant, semantic dementia, and progressive non-fluent aphasia. Among these subtypes, behavioral variant FTD is the most commonly observed type of dementia associated with motor neuron disorders (Bird et al., 1999). The incidence of FTD is approximately 4.0 new cases per 100,000 population per year, with 40% of cases being familial (Ratnavalli et al., 2002). Similar to ALS and other neurological disorders, there is no effective treatment for FTD (Tsai and Boxer, 2014).

It is now recognized that ALS and FTD are two diseases that form a broad neurodegenerative continuum. One of the earliest hints of this overlap came from the clinical observation that both disorders can be present within the same family or even within the same individual. Cross-sectional studies performed over the last decade estimate that up to 50% of ALS patients develop cognitive impairment associated with FTD. Similarly, up to 30% of FTD patients develop motor dysfunction (Burrell et al., 2011).

Considerable progress has been made in unraveling the genetics of ALS and FTD, and it is now clear that the genetics of these two neurodegenerative conditions overlap significantly. TARDBP, SQSTM1, VCP, FUS, TBK1, CHCHD10, and most importantly C9orf72, are the critical genetic players, and their discoveries have implicated autophagy, RNA processing, and vesicle and inclusion formation as the central pathways involved in these forms of neurodegeneration.

Here we provide a summary of the significant genes identified in these two intrinsically linked neurodegenerative diseases and highlight where cross-talk exists. We describe the genes in the order of their relevance to ALS/FTD overlap, ranging from genes that have been demonstrated to cause both clinically and neuropathologically confirmed ALS and FTD to genes where the cognitive or motor symptoms are reported in the literature but pathological confirmation in not yet available.

The genes described in this review, clinical phenotypes and pathways associated with them are summarized in Table 1.

TABLE 1.

Key genes identified in ALS and FTD.

Chromosome 9 Open Reading Frame 72 (C9Orf72)

In 2011, a hexanucleotide repeat expansion within the C9orf72 gene located on chromosome 9p21 was identified as a significant genetic cause of both ALS and FTD (DeJesus-Hernandez et al., 2011; Renton et al., 2011). This repeat expansion is the most common genetic cause of ALS, FTD, and ALS/FTD responsible for ∼11% of all ALS and ∼13% of all FTD cases. This discovery demonstrated that there is a more considerable genetic overlap between ALS and FTD than had been previously estimated. The majority of C9orf72-related FTD cases manifest behavioral symptoms with a much smaller percentage presenting with semantic dementia or with progressive non-fluent aphasia. C9orf72 repeat expansions have also been implicated as rare causes of other neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, progressive supranuclear palsy, ataxia, corticobasal syndrome, Huntington disease-like syndrome, and Creutzfeldt–Jakob disease (Beck et al., 2013; Hensman Moss et al., 2014; Devenney et al., 2018).

Several mechanisms have been proposed to explain how C9orf72 expansion causes neurological disease. These include (Cleveland and Rothstein, 2001) haploinsufficiency of C9orf72 protein (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Chio et al., 2013; Shi et al., 2018; Shao et al., 2019) RNA toxicity due to accumulation of RNA containing the GGGGCC repeat in the brain and spinal cord (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Arthur et al., 2016; Arzberger et al., 2018) dipeptide repeat (DPR) protein toxicity arising from repeat-associated non-AUG translation occurring off the expansion (Miller et al., 2012; May et al., 2014; Freibaum and Taylor, 2017) disruption of the nucleocytoplasmic transport (Freibaum et al., 2015; Jovicic et al., 2015; Zhang et al., 2015). Although the data for each of these mechanisms are compelling, it is not yet clear which of them plays the dominant role in determining neurodegeneration. The possibility of multiple mechanisms, operating in either unison or sequentially to bring about neuronal death, cannot be discounted.

Various mouse models have been created to elucidate the pathogenic mechanism underlying C9orf72 neurodegeneration. Though informative, these models have failed to resolve the exact mechanism, as the available information bolsters all four modes of neurodegeneration. For example, mice lacking C9orf72 in neurons and glial cells did not display motor neuron degeneration or defects in motor function associated with ALS (Koppers et al., 2015). BAC transgenic mice with expanded human C9orf72 hexanucleotide repeat that ranged between 100 and 1000 repeats developed RNA foci and dipeptide repeat proteins throughout the nervous system. However, there was no evidence of neurodegeneration or functional deficits (O’Rourke et al., 2015; Peters et al., 2015). Mice with more than 450 GGGGCC repeats have mild hippocampal neuronal loss and display signs of age-dependent anxiety and impaired cognitive functioning (Jiang et al., 2016).

More recent mouse models showed that that loss of C9orf72 in a gain-of-function C9ALS/FTD mouse model aggravates motor behavior deficits in a dose-dependent manner (Shao et al., 2019). Transgenic GFP-PR28 mice expressing arginine-rich poly(PR), the most toxic type of DPRs in neurons, did partially develop neuropathological features of C9FTD/ALS (Hao et al., 2019). Two other transgenic C9FTD/ALS mouse models demonstrated that poly(GR) affects translation and stress granule dynamics (Zhang et al., 2018) and compromises mitochondrial function by binding Atp5a1 (Choi et al., 2019).

TAR DNA-Binding Protein 43 (TARDBP)

Mutations in the TAR DNA-binding protein 43 (the gene that encodes the TDP-43 protein) were linked to ALS in 2008 (Sreedharan et al., 2008). Before that, it was recognized that TDP-43 cytoplasmic and nuclear inclusions are characteristic of both ALS and FTD. In ALS, the cytoplasmic accumulation of TDP-43 is found in neurons and glia of the primary motor cortex, brainstem motor nuclei, and spinal cord (Bodansky et al., 2010; Mackenzie et al., 2010). In FTD, the inclusions are observed in the neocortex and dentate granule cells of the hippocampus (Neumann et al., 2006; Davidson et al., 2007). TDP-43 mutations are the cause of ∼ 1% of all ALS cases. In contrast, an even smaller number of FTD cases arising from mutations in this gene have been described, despite the widespread presence of TDP-43 in FTD brains (Tan et al., 2017).

TDP-43 is a DNA and RNA binding protein involved in many aspects of RNA metabolism, including splicing, microRNA biogenesis, transcription, and stabilization of messenger RNA (Buratti et al., 2001; Strong et al., 2007; Buratti and Baralle, 2008; Fiesel et al., 2010; Lagier-Tourenne et al., 2010). Two contrasting mechanisms have been proposed to explain TDP-43 related neurodegeneration, namely (Cleveland and Rothstein, 2001) loss of function arising from sequestration of critical TDP-43 protein within cytoplasmic aggregates leading to nuclear depletion of TDP-43 (Chio et al., 2013; Mitra et al., 2019; Roczniak-Ferguson and Ferguson, 2019) gain of function effect due to some inherent toxic property of the aggregates (Buratti and Baralle, 2012; Hergesheimer et al., 2019). However, the toxic role of aggregated TDP-43 in neurodegeneration is still under debate. Recent research has focused on the role of stress granules in the pathogenesis of TDP43-related ALS (Khalfallah et al., 2018). TDP-43 mutations have also been reported to alter liquid drop formation, though the pathophysiological role of this in vitro epiphenomena remains unclear (Conicella et al., 2016).

More than fifteen mouse models have been created in the last 2 years in an attempt to decipher the pathogenic roles of TDP-43 in autophagy, protein homeostasis, and clearance pathways involved in ALS and FTD. These rodent models showed that suppression of conditional TDP-43 transgene expression differentially affects early cognitive and social phenotypes in TDP-43 mice (Silva et al., 2019). In a TDP-43Q331K/Q331K knock-in mouse model of ALS-FTD, TDP-43 gains function due to impaired autoregulation (White et al., 2018b). In TDP-43M337V and TDP-43G298S knock-in mice, mutant TDP-43 causes early stage dose-dependent motor neuron degeneration (Ebstein et al., 2019). Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of motor neuron degeneration (Fratta et al., 2018). Mouse models have also provided insight into how mutations in this gene may be underlying frontotemporal dementia. A recent TDP-43Q331K mouse model manifested cognitive dysfunction in the absence of motor dysfunction. Pathological examination showed that normal localization of TDP-43 within the cell, but there was evidence of perturbed regulation of TDP-43 (White et al., 2018a, b).

Sequestosome-1 (SQSTM1)

Mutations in Sequestosome-1 (SQSTM1) was initially discovered in patients with Paget’s disease of bone (Laurin et al., 2002) and linked to ALS and behavioral FTD in 2011 (Fecto et al., 2011). SQSTM1 encodes p62, a multifunctional protein involved in a wide range of cellular functions, including apoptosis (Jung and Oh, 2019), NFKB1 signaling (Foster et al., 2019), ubiquitin-mediated autophagy (Zaffagnini et al., 2018; Gao et al., 2019; Park et al., 2019), and transcription regulation (Rea et al., 2013). p62 is also a standard component of ubiquitin-containing inclusions in several neurological disorders, including ALS and FTD. More than 100 variants have been identified in SQSTM1, and cumulatively they account for ∼1% of all ALS and up to 3% of all FTD cases. Defective p62 is prone to forming aggregates. Individuals with SQSTM1 variants have p62-positive inclusions in the motor neurons if presenting with ALS, and in the hippocampus and cerebral neocortex if presenting with FTD (Arai et al., 2003; Teyssou et al., 2013).

Accumulation of SQSTM1 comes from disturbances in the selective autophagy pathway (Deng et al., 2019). However, the pathogenic mechanism that contributes to SQSTM1-related impaired autophagy and degradation remains poorly understood. Similar to TDP-43 and FUS, SQSTM1 goes through liquid-liquid phase separation. Recent research shows that cytoplasmic DAXX drives SQSTM1/p62 phase condensation, an essential step in the activation of Nrf2-mediated stress response (Yang et al., 2019). Polyubiquitin chain-induced p62 phase separation leads to the segregation of autophagic cargo (Herhaus and Dikic, 2018; Sun et al., 2018).

To date, no. p62 mouse model has been created to study the direct effect of p62 mutations in ALS/FTD. However, many mouse models exist that demonstrate a relationship between p62 and other ALS genes. Mitsui et al. (2018) previously reported that loss of SQSTM1 exacerbates disease phenotypes in SOD1H46R ALS mice. Following the initial report, the same authors demonstrated that SQSTM1 overexpression results in a significant increase in biochemically detectable insoluble SQSTM1 and poly-ubiquitinated proteins in the spinal cord of SQSTM1; SOD1H46R mice when compared to SOD1H46R mice. This observation suggests that overexpression of p62 in SOD1H46R mice accelerates disease onset by impairing the protein degradation pathways (Mitsui et al., 2018).

From the FTD perspective, apart from developing mature-onset obesity due to impaired glucose tolerance and insulin resistance, p62 knockout mice display significantly reduced life span and accelerated aging phenotypes. These mice develop cognitive impairment and anxiety, which are symptoms characteristic of human Alzheimer’s disease (Kwon et al., 2012).

Fused in Sarcoma (FUS)

Fused in sarcoma (FUS) is an RNA-binding protein that was linked to ALS in 2009 (Kwiatkowski et al., 2009). Similar to TDP-43, FUS is involved in multiple aspects of RNA metabolism regulation, including alternative splicing, RNA translation, and transport (Kwiatkowski et al., 2009; Vance et al., 2009). Mutations in FUS are responsible for ∼1% of all ALS. They are also occasionally observed in behavioral FTD cases. In addition to these phenotypes, abnormal aggregates of FUS, independently of their mutations, are present in other neurodegenerative diseases such as hereditary essential tremor, the polyglutamine diseases, and Parkinson’s disease.

Amyotrophic lateral sclerosis and FTD related mutations are clustered in highly conserved regions of the gene and affect the protein nuclear localization signal (NLS). Similar to TDP-43, mutations in the FUS gene are predominantly found in ALS patients. A limited number of FUS mutations (p.P106L, p.Gly174-Gly175 deletion GG, p.M254V) have been described in FTD patients without concomitant ALS (Van Langenhove et al., 2010; Huey et al., 2012).

Two mechanisms were proposed to explain FUS-related neurodegeneration. First of all, there is the toxic gain-of-function in which nuclear FUS aggregates in cytoplasm and spreads in a prion-like manner through neuronal tissues (Armstrong, 2017). Second, the depletion of FUS from the nucleus may impair transcription, alternative splicing, and DNA repair (Shang and Huang, 2016). A reasonable amount of evidence supports both mechanisms, and different mechanisms may stand behind different FUS mutations (Ishigaki and Sobue, 2018; An et al., 2019). Liquid–liquid phase separation (LLPS) of FUS has emerged recently as an alternative mechanism for FUS-related neurodegeneration. It is now established that LLPS is modulated by universal cellular actors such as ATP and nucleic acids through enhancement and dissolution (Kang et al., 2019). Other recent FUS studies expanded on LLPS functions, mechanism, and transformation (Berry et al., 2018; Kang et al., 2019; Murthy et al., 2019; Niaki et al., 2019).

Multiple mouse models have been created in an attempt to identify the pathogenic roles of FUS in neurodegeneration. FUS knockout mice display behavioral abnormalities such as hyperactivity and reduced anxiety-related behavior. However, they do not develop motor neuron impairment, suggesting that the ablation of the FUS gene alone is insufficient to cause ALS (Kino et al., 2015). Transgenic mice overexpressing exogenous FUS with nuclear localization signal deletion (ΔNLS-FUS) under Thy1 neuron-specific promoter develop progressive ALS phenotypes associated with the formation of ubiquitin/p62-positive FUS aggregates, neuronal loss, and gliosis. In FusΔNLS/ΔNLS mice, truncation of the NLS region leads to mislocalization of FUS protein from the nucleus to the cytoplasm in spinal motor neurons and cortical neurons where it leads to apoptosis (Scekic-Zahirovic et al., 2016). Furthermore, both FusΔNLS/+mice and knock-in mice carrying another C-terminal frameshift mutation (FusΔ14/+) develop progressive motor neuron loss in heterozygosity, recapitulating the early stages of disease (Scekic-Zahirovic et al., 2016; Devoy et al., 2017). More recent FUSR514G and FUSR521C transgenic mice models show that overriding the FUS autoregulation system triggers gain-of-function toxicity via an altered autophagy-lysosome pathway and impaired RNA metabolism (Ho and Ling, 2019; Ling et al., 2019).

Valosin Containing Protein (VCP)

Mutations in Valosin containing protein (VCP) was initially discovered as the cause of a clinical syndrome characterized by the triad of inclusion body myopathy, Paget’s disease of bone, and frontotemporal dementia (IBMFTD) in 2004 (Watts et al., 2004). Mutations in this gene were subsequently identified as a cause of ALS, representing an early example of how genetic mutations in a single gene could underlie both ALS and FTD (Johnson et al., 2010). To date, 72 autosomal dominant mutations have been discovered in this gene, more than 30 of which are reported in ALS or FTD cases (including behavioral FTD, semantic dementia, and progressive non-fluent aphasia) (Al-Obeidi et al., 2018; Saracino et al., 2018; Bastola et al., 2019). Many of the reported VCP mutations are located on exon five within the N-terminal CDC48 domain, which is involved in ubiquitin-binding, meaning that mutations in this region may negatively affect the ubiquitin protein degradation pathway (Ganji et al., 2018; Twomey et al., 2019).

A recent study by Al-Obeidi et al. (2018) showed that VCP mutations are present in ∼9% of ALS, 4% of Parkinson’s disease, and 2% of Alzheimer’s disease patients. As of today, no definite correlation between the mutation type and the incidence of clinical features associated with VCP has been established (Al-Obeidi et al., 2018; Plewa et al., 2018).

Valosin Containing Protein encodes a member of the AAA-ATPase enzyme family with wide-ranging functions in cell division (Ogura and Wilkinson, 2001), DNA repair, ubiquitin-dependent protein degradation, and suppression of apoptosis (Ogura and Wilkinson, 2001). Ludtmann et al. (2017) provides evidence that mutations in VCP lead to mitochondrial uncoupling due to a reduced ADP/ATP translocation by adenine nucleotide translocase. Such deficiency in mitochondrial bioenergetics makes neurons especially vulnerable as they require more energy than other cell types (Ludtmann et al., 2017).

Recent mouse models of VCP showed that activation of the NLRP3 inflammasome is associated with VCP protein myopathy. Nalbandian et al. (2017) reported a significant increase in the expression of NLRP3, Caspase 1, IL-1β, and IL-18 in the quadriceps of 12 and 24 months old VCPR155H/+heterozygous mice. Furthermore, a significant increase of IL-1β(+)F4/80(+)Ly6C(+) macrophages in the quadriceps and bones of the same mice were also observed and is positively correlated with high expression levels of TDP-43 and p62/SQSTM1 markers of VCP pathology and progressive muscle wasting (Nalbandian et al., 2017).

Another recent discovery showed that VCP plays a vital role in the maintenance of lysosomal homeostasis and TFEB activity in differentiated skeletal muscle (Arhzaouy et al., 2019). Arhzaouy et al. (2019) showed that selective inactivation of VCP in skeletal muscles of Myl1p-cre-vcp-/-mice, results in a necrotic myopathy with increased macroautophagic/autophagic proteins and damaged lysosomes. It was further demonstrated that the myofiber necrosis was preceded by the upregulation of LGALS3/Galectin-3, a marker of damaged lysosomes, and TFEB activation, suggesting early defects in the lysosomal system (Arhzaouy et al., 2019).

Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10 (CHCHD10)

Coiled-coil-helix-coiled-coil-helix domain-containing protein 10 (CHCHD10) is a mitochondrial protein associated with ALS and FTD, including the behavioral and primary progressive aphasia subtypes of this form of dementia (Ajroud-Driss et al., 2015; Cozzolino et al., 2015). The protein was discovered in 2014 by exome sequencing of a large French family affected by autosomal dominant FTD with or without ALS, cerebellar ataxia, and mitochondrial myopathy (Chaussenot et al., 2014). At least 30 variants have since been reported, and they are concentrated on exon two of the gene encoding the non-structured N-terminal (Taylor et al., 2016; Perrone et al., 2017; Zhou et al., 2017).

Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10 is a multifunctional protein involved in the regulation of mitochondrial metabolism, synthesis of respiratory chain components, and modulation of cell apoptosis (Zhou et al., 2017). Perhaps not surprisingly, mutations in CHCHD10 lead to disassembly of the mitochondrial contact site complex, severe mitochondrial DNA repair deficiency after oxidative stress, disruption of oxygen consumption and ATP synthesis in cells, and disturbance of apoptotic mechanisms (Zhou et al., 2017).

Recent data shows enrichment of CHCHD10 expression at the postsynaptic membrane of neuromuscular junctions (Bannwarth et al., 2014; Zhou et al., 2017; Xiao et al., 2019). Deletion of CHCHD10 in skeletal muscle of HSA-CHCHD10-/- knockout mice results in motor defects and neurotransmission impairment, indicating that muscle CHCHD10 is required for normal neurotransmission between motoneurons and skeletal muscle fibers (Xiao et al., 2019). Furthermore, an examination of HSA-CHCHD10-/- mice mitochondria under an electron microscope revealed a large quantity of large lysosome-like vesicles, indicating active mitochondria degradation and suggesting that CHCHD10 is required for mitochondria structure and ATP production (Burstein et al., 2018; Xiao et al., 2019).

Two groups independently developed CHCHD10S55L knock-in mice, representative of human CHCHD10 S59L mutation, and found that these mice developed progressive motor deficits, myopathy, cardiomyopathy, and died prematurely (Anderson et al., 2019; Genin et al., 2019). Histological examination revealed that CHCHD10, together with its twin CHCHD2 forms aggregates resulting in abnormal organelle morphology and function. In contrast, knock out CHCHD10 mice containing a single adenine nucleotide insertion in exon two that results in a prematurely terminated protein, did not develop similar pathology, suggesting that tissue-specific toxic gain-of-function is the likely mechanism behind CHCHD10 S59L related neurodegeneration (Anderson et al., 2019).

TANK-Binding Kinase 1 (TBK1)

TANK-binding kinase 1 (TBK1) gene was discovered in 2015 through the whole-exome sequencing analysis of a large case-control cohort (Cirulli et al., 2015; Freischmidt et al., 2015). In 2016, a large genome-wide association study (GWAS) also identified the TBK1 gene on chromosome 12q14.2 as a risk locus for ALS, thus confirming the gene’s association with motor neuron degeneration (van Rheenen et al., 2016). TBK1 is a member of the IkB kinase family involved in autophagy, mitophagy, and innate immune signaling (Weidberg and Elazar, 2011). The protein is highly expressed in neuronal cells of the cerebral cortex, hippocampus, and lateral ventricle (Uhlen et al., 2015). It also interacts with other genes implicated in ALS, such as OPTN and SQSTM1, to form TBK1 autophagic adaptor complex (Ryzhakov and Randow, 2007; Morton et al., 2008; Li et al., 2016).

To date, more than 90 mutations have been discovered on TBK1. According to a recent meta-analysis study, TBK1 loss of function and missense mutations account for 1.0 and 1.8% in ALS/FTD patients, respectively (Lamb et al., 2019). The majority of TBK1 mutations are loss of function that result in the deletion of the C-terminal domain responsible for interaction with adaptor proteins that regulate the cellular distribution of TBK1 and activation of downstream signaling pathways (Ryzhakov and Randow, 2007). Indeed, mutations appear to lead to a significant decrease in TBK1 expression at the mRNA and protein levels (Freischmidt et al., 2015).

TANK-binding kinase 1 mutations are associated with bulbar onset ALS and fast progressing behavioral FTD (Freischmidt et al., 2015). In ALS patients, TBK1 mutations are pathologically characterized by TDP-43 positive and p62 positive inclusions in motor neurons, as well as TDP-43 inclusions in the cortex. Similar to that observed in ALS, FTD patients, harboring TBK1 mutations is also characterized by TDP-43 inclusions in numerous brain regions and cytoplasmic p62 and ubiquitin-positive inclusions in glial cells (Van Mossevelde et al., 2016).

Compelling evidence exists that loss-of-function is the pathological mechanism behind TBK1-related ALS and FTD (de Majo et al., 2018; Lamb et al., 2019; Weinreich et al., 2019). Germline deletion of TBK1 is lethal in embryonic mice suggesting that the protein plays a critical role in developmental homeostasis (Bonnard et al., 2000). More recent rodent models demonstrated that conditional neuron-specific knockout of Tbk1 in Tbk1fl/fl Nestin-Cre mice leads to the development of cognitive and motor dysfunction similar to ALS/FTD. Neuron-specific Tbk1 deletion induces morphological and biochemical alterations in neurons and glia such as abnormal dendrites, neurofibrillary tangles, reduced dendritic spine density, as well as cortical synapse loss. Furthermore, Tbk1 knockout impairs autophagy in motor neuron-like cells, while Tbk1 over-expression extends survival of ALS transgenic mice (Duan et al., 2019).

TANK-Binding Kinase 1 is a central regulator of selective autophagy and inflammatory responses via IFN type I signaling (Perry et al., 2004; Hu et al., 2018). Heterozygous deletion of the α-IFN receptor Ifnar1 significantly prolongs the life span of SOD1G93A ALS mice (Wang et al., 2011). In a 2019 study, Brenner et al. (2019) further elucidated on the connection between TBK1 and SOD1 in the mouse models. The group showed that at the early stage, heterozygous Tbk1 deletion impairs autophagy in motoneurons and prepones the clinical onset and muscular denervation in SOD1G93A/Tbk1 ± mice, while at the late disease stage, it significantly alleviates microglial neuroinflammation, decelerates disease progression, and extends mouse survival (Brenner et al., 2019).

Summary

After several decades of research, it is now clear that the same genes can cause ALS and FTD. Mutations in C9orf72, TARDBP, FUS, TBK1, VCP, CHCHD10, and SQSTM1 are the most closely associated with both diseases. Clinically, the ALS phenotype is most commonly associated with the behavioral variant of FTD, with other subtypes of FTD involving language occurring less commonly. The pathophysiology underlying this observation is poorly understood.

Nevertheless, this overlap is not complete: SOD1, FUS, and TDP-43 variants are most commonly associated with ALS and are only rarely found in FTD patients. Similarly, GRN is linked to FTD, but not to ALS. Clinically, the ALS phenotype is most commonly associated with the behavioral variant of FTD, with other subtypes of FTD involving language occurring less commonly. The pathophysiology underlying this observation is poorly understood.

It is striking how the same pathways are implicated repeatedly in ALS and FTD. Both disorders characterized by defects in RNA processing, protein clearance by autophagy, vesicle trafficking, mitochondrial dysfunction, and impaired protein homeostasis. The genes described in this review are the key players in these pathways. TDP-43 and FUS are responsible for RNA regulation; SQSTM1, C9orf72, VCP, and TBK1 are involved in autophagy and vesicle dynamics; TDP-43, FUS, and SQSTM1 are common components of nuclear and cytoplasmic inclusions (Weishaupt et al., 2016). Due to such significant genetic overlap between ALS and FTD, it is reasonable to look in FTD cases for mutations in ALS genes, and vice-versa.

The C9orf72 repeat expansion gives rise to a diverse range of inter-familial and intra-familial phenotypes, including age at disease onset, site of symptom onset, rate and pattern of progression, levels of cognitive impairment and motor neuron degeneration, as well as disease duration. This clinical heterogeneity likely indicates that both genetic and environmental factors play a significant role in the development and course of the disease. Environmental factors such as occupational exposure to heavy metals, toxic compounds, and extremely low-frequency electromagnetic frequencies have been previously reported to increase the risk of developing neurological disorders. Studies on personal habits revealed an increased risk of ALS among smokers, as well as an overall worse prognosis after disease onset. In contrast, alcohol consumption was associated with a reduced risk of ALS. Literature analysis of head trauma and the development of neurological disorders were inconclusive. More recently, advanced genetic analysis of a large genetic dataset implicated high cholesterol as driving the risk of ALS, as well as confirming an association with smoking and physical exercise (Bandres-Ciga et al., 2019).

Research shows that environmental factors can influence people’s chances of developing ALS or FTD. Nevertheless, the studies were performed on case cohorts that were not genetically selected. Different sets of environmental factors may interact with different genes. Consequently, future genetic epidemiology efforts should focus on cohorts selected based on their underlying genetic risk. Studying such population-based cohorts that have been assiduously collected and phenotyped for clinical features, genetics, epigenetics, and environmental and lifestyle exposures will be essential to these efforts.

Author Contributions

YA drafted the manuscript. PF, RC, and BT participated in critically revising the manuscript for important intellectual content. All authors read and approved the final manuscript.

Conflict of Interest

BT has a European patent granted and US patent pending on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of C9orf72. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling Editor declared a past co-authorship with one of the authors BT. The reviewer PM declared a past co-authorship with one of the authors BT to the handling Editor.

Footnotes

Funding. This work was supported in part by the Intramural Research Programs of the U.S. National Institutes of Health, National Institute on Aging (Z01-AG000949-02) and the National Institute of Neurological Disorders and Stroke. This work was also supported by University College London.

References

1. Ajroud-Driss S., Fecto F., Ajroud K., Lalani I., Calvo S. E., Mootha V. K., et al. (2015). Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy._Neurogenetics_16 1–9. 10.1007/s10048-014-0421-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Al-Obeidi E., Al-Tahan S., Surampalli A., Goyal N., Wang A. K., Hermann A., et al. (2018). Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy._Clin. Genet._93 119–125. 10.1111/cge.13095 [DOI] [PMC free article] [PubMed] [Google Scholar]
3. An H., Skelt L., Notaro A., Highley J. R., Fox A. H., La Bella V., et al. (2019). ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles._Acta Neuropathol. Commun._7:7. 10.1186/s40478-019-0658-x [DOI] [PMC free article] [PubMed] [Google Scholar]
4. Anderson C. J., Bredvik K., Burstein S. R., Davis C., Meadows S. M., Dash J., et al. (2019). ALS/FTD mutant CHCHD10 mice reveal a tissue-specific toxic gain-of-function and mitochondrial stress response._Acta Neuropathol._138 103–121. 10.1007/s00401-019-01989-y [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Arai T., Nonaka T., Hasegawa M., Akiyama H., Yoshida M., Hashizume Y., et al. (2003). Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62._Neurosci. Lett._342 41–44. [DOI] [PubMed] [Google Scholar]
6. Arhzaouy K., Papadopoulos C., Schulze N., Pittman S. K., Meyer H., Weihl C. C. (2019). VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle._Autophagy_15 1082–1099. 10.1080/15548627.2019.1569933 [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Armstrong R. A. (2017). Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns._Folia Neuropathol._55 185–192. 10.5114/fn.2017.70482 [DOI] [PubMed] [Google Scholar]
8. Arthur K. C., Calvo A., Price T. R., Geiger J. T., Chio A., Traynor B. J. (2016). Projected increase in amyotrophic lateral sclerosis from 2015 to 2040._Nat. Commun._7:12408. 10.1038/ncomms12408 [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Arzberger T., Schludi M. H., Lehmer C., Schmid B., Edbauer D. (2018). RNA versus protein toxicity in C9orf72 ALS/FTLD._Acta Neuropathol._135 475–479. [DOI] [PubMed] [Google Scholar]
10. Bandres-Ciga S., Noyce A. J., Hemani G., Nicolas A., Calvo A., Mora G., et al. (2019). Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis._Ann. Neurol._85 470–481. 10.1002/ana.25431 [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E. C., Lacas-Gervais S., Fragaki K., et al. (2014). A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement._Brain_137(Pt 8), 2329–2345. 10.1093/brain/awu138 [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Bastola P., Bilkis R., De Souza C., Minn K., Chien J. (2019). Heterozygous mutations in valosin-containing protein (VCP) and resistance to VCP inhibitors._Sci. Rep._9:11002. 10.1038/s41598-019-47085-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
13. Beck J., Poulter M., Hensman D., Rohrer J. D., Mahoney C. J., Adamson G., et al. (2013). Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population._Am. J. Hum. Genet._92 345–353. 10.1016/j.ajhg.2013.01.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
14. Berry J., Brangwynne C. P., Haataja M. (2018). Physical principles of intracellular organization via active and passive phase transitions._Rep. Prog. Phys._81:046601. 10.1088/1361-6633/aaa61e [DOI] [PubMed] [Google Scholar]
15. Bird T. D., Nochlin D., Poorkaj P., Cherrier M., Kaye J., Payami H., et al. (1999). A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L)._Brain_122(Pt 4), 741–756. [DOI] [PubMed] [Google Scholar]
16. Bodansky A., Kim J. M., Tempest L., Velagapudi A., Libby R., Ravits J. (2010). TDP-43 and ubiquitinated cytoplasmic aggregates in sporadic ALS are low frequency and widely distributed in the lower motor neuron columns independent of disease spread._Amyotroph. Lateral. Scler._11 321–327. 10.3109/17482961003602363 [DOI] [PMC free article] [PubMed] [Google Scholar]
17. Bonnard M., Mirtsos C., Suzuki S., Graham K., Huang J., Ng M., et al. (2000). Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription._EMBO J._19 4976–4985. [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Brenner D., Sieverding K., Bruno C., Luningschror P., Buck E., Mungwa S., et al. (2019). Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice._J. Exp. Med._216 267–278. 10.1084/jem.20180729 [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Buratti E., Baralle F. E. (2008). Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease._Front Biosci._13:867–878. [DOI] [PubMed] [Google Scholar]
20. Buratti E., Baralle F. E. (2012). TDP-43: gumming up neurons through protein-protein and protein-RNA interactions._Trends Biochem. Sci._37 237–247. 10.1016/j.tibs.2012.03.003 [DOI] [PubMed] [Google Scholar]
21. Buratti E., Dork T., Zuccato E., Pagani F., Romano M., Baralle F. E. (2001). Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping._EMBO J._20 1774–1784. [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Burrell J. R., Kiernan M. C., Vucic S., Hodges J. R. (2011). Motor neuron dysfunction in frontotemporal dementia._Brain_134(Pt 9), 2582–2594. 10.1093/brain/awr195 [DOI] [PubMed] [Google Scholar]
23. Burstein S. R., Valsecchi F., Kawamata H., Bourens M., Zeng R., Zuberi A., et al. (2018). In vitro and in vivo studies of the ALS-FTLD protein CHCHD10 reveal novel mitochondrial topology and protein interactions._Hum. Mol. Genet._27 160–177. 10.1093/hmg/ddx397 [DOI] [PMC free article] [PubMed] [Google Scholar]
24. Chaussenot A., Le Ber I., Ait-El-Mkadem S., Camuzat A., de Septenville A., Bannwarth S., et al. (2014). Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients._Neurobiol. Aging_35 e1–e4. 10.1016/j.neurobiolaging.2014.07.022 [DOI] [PubMed] [Google Scholar]
25. Chio A., Logroscino G., Traynor B. J., Collins J., Simeone J. C., Goldstein L. A., et al. (2013). Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature._Neuroepidemiology_41 118–130. 10.1159/000351153 [DOI] [PMC free article] [PubMed] [Google Scholar]
26. Choi S. Y., Lopez-Gonzalez R., Krishnan G., Phillips H. L., Li A. N., Seeley W. W., et al. (2019). C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo._Nat. Neurosci._22 851–862. 10.1038/s41593-019-0397-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Cirulli E. T., Lasseigne B. N., Petrovski S., Sapp P. C., Dion P. A., Leblond C. S., et al. (2015). Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways._Science_347 1436–1441. 10.1126/science.aaa3650 [DOI] [PMC free article] [PubMed] [Google Scholar]
28. Cleveland D. W., Rothstein J. D. (2001). From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS._Nat. Rev. Neurosci._2 806–819. [DOI] [PubMed] [Google Scholar]
29. Conicella A. E., Zerze G. H., Mittal J., Fawzi N. L. (2016). ALS mutations disrupt phase separation mediated by alpha-helical structure in the TDP-43 low-complexity C-terminal domain._Structure_24 1537–1549. 10.1016/j.str.2016.07.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
30. Cozzolino M., Rossi S., Mirra A., Carri M. T. (2015). Mitochondrial dynamism and the pathogenesis of Amyotrophic Lateral Sclerosis._Front. Cell Neurosci._9:31. 10.3389/fncel.2015.00031 [DOI] [PMC free article] [PubMed] [Google Scholar]
31. Davidson Y., Kelley T., Mackenzie I. R., Pickering-Brown S., Du Plessis D., Neary D., et al. (2007). Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein. TDP-43._Acta Neuropathol._113 521–533. [DOI] [PubMed] [Google Scholar]
32. de Majo M., Topp S. D., Smith B. N., Nishimura A. L., Chen H. J., Gkazi A. S., et al. (2018). ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function._Neurobiol. Aging_71 e1–e10. 10.1016/j.neurobiolaging.2018.06.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
33. DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., Boxer A. L., Baker M., Rutherford N. J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS._Neuron_2011 245–256. 10.1016/j.neuron.2011.09.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
34. Deng Z., Lim J., Wang Q., Purtell K., Wu S., Palomo G. M., et al. (2019). ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway._Autophagy_10.1080/15548627.2019.1644076 [Epub ahead of print], [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Devenney E. M., Ahmed R. M., Halliday G., Piguet O., Kiernan M. C., Hodges J. R. (2018). Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members._Neurology_91 e1498–e1507. 10.1212/WNL.0000000000006344 [DOI] [PubMed] [Google Scholar]
36. Devoy A., Kalmar B., Stewart M., Park H., Burke B., Noy S. J., et al. (2017). Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in ‘FUSDelta14’ knockin mice._Brain_140 2797–2805. 10.1093/brain/awx248 [DOI] [PMC free article] [PubMed] [Google Scholar]
37. Duan W., Guo M., Yi L., Zhang J., Bi Y., Liu Y., et al. (2019). Deletion of Tbk1 disrupts autophagy and reproduces behavioral and locomotor symptoms of FTD-ALS in mice._Aging_11 2457–2476. 10.18632/aging.101936 [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Ebstein S. Y., Yagudayeva I., Shneider N. A. (2019). Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a tardbp knockin mouse model of ALS._Cell Rep_26:364-373e4. 10.1016/j.celrep.2018.12.045 [DOI] [PubMed] [Google Scholar]
39. Fecto F., Yan J., Vemula S. P., Liu E., Yang Y., Chen W., et al. (2011). SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis._Arch Neurol._68 1440–1446. 10.1001/archneurol.2011.250 [DOI] [PubMed] [Google Scholar]
40. Fiesel F. C., Voigt A., Weber S. S., Van den Haute C., Waldenmaier A., Gorner K., et al. (2010). Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6._EMBO J._29 209–221. 10.1038/emboj.2009.324 [DOI] [PMC free article] [PubMed] [Google Scholar]
41. Foster A., Scott D., Layfield R., Rea S. L. (2019). An FTLD-associated SQSTM1 variant impacts Nrf2 and NF-kappaB signalling and is associated with reduced phosphorylation of p62._Mol. Cell Neurosci._98 32–45. 10.1016/j.mcn.2019.04.001 [DOI] [PubMed] [Google Scholar]
42. Fratta P., Sivakumar P., Humphrey J., Lo K., Ricketts T., Oliveira H., et al. (2018). Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis._EMBO J._37:e98684. 10.15252/embj.201798684 [DOI] [PMC free article] [PubMed] [Google Scholar]
43. Freibaum B. D., Lu Y., Lopez-Gonzalez R., Kim N. C., Almeida S., Lee K. H., et al. (2015). GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport._Nature_525 129–133. 10.1038/nature14974 [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Freibaum B. D., Taylor J. P. (2017). The role of dipeptide repeats in C9ORF72-related ALS-FTD._Front. Mol. Neurosci._10:35. 10.3389/fnmol.2017.00035 [DOI] [PMC free article] [PubMed] [Google Scholar]
45. Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., Muller K., et al. (2015). Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia._Nat. Neurosci._18 631–636. 10.1038/nn.4000 [DOI] [PubMed] [Google Scholar]
46. Ganji R., Mukkavalli S., Somanji F., Raman M. (2018). The VCP-UBXN1 complex mediates triage of ubiquitylated cytosolic proteins bound to the BAG6 complex._Mol. Cell Biol._38:MCB.00154-118. 10.1128/MCB.00154-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Gao J., Perera G., Bhadbhade M., Halliday G. M., Dzamko N. (2019). Autophagy activation promotes clearance of alpha-synuclein inclusions in fibril-seeded human neural cells._J. Biol. Chem._294 14241–14256. 10.1074/jbc.RA119.008733 [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Genin E. C., Madji Hounoum B., Bannwarth S., Fragaki K., Lacas-Gervais S., Mauri-Crouzet A., et al. (2019). Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10(S59L/+) mouse._Acta Neuropathol._138 123–145. 10.1007/s00401-019-01988-z [DOI] [PubMed] [Google Scholar]
49. Hao Z., Liu L., Tao Z., Wang R., Ren H., Sun H., et al. (2019). Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR._Nat. Commun._10:2906. 10.1038/s41467-019-10956-w [DOI] [PMC free article] [PubMed] [Google Scholar]
50. Hensman Moss D. J., Poulter M., Beck J., Hehir J., Polke J. M., Campbell T., et al. (2014). C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies._Neurology_82 292–299. 10.1212/WNL.0000000000000061 [DOI] [PMC free article] [PubMed] [Google Scholar]
51. Hergesheimer R. C., Chami A. A., de Assis D. R., Vourc’h P., Andres C. R., Corcia P., et al. (2019). The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?_Brain_142 1176–1194. 10.1093/brain/awz078 [DOI] [PMC free article] [PubMed] [Google Scholar]
52. Herhaus L., Dikic I. (2018). Ubiquitin-induced phase separation of p62/SQSTM1._Cell Res._28 389–390. [DOI] [PMC free article] [PubMed] [Google Scholar]
53. Ho W. Y., Ling S. C. (2019). Elevated FUS levels by overriding its autoregulation produce gain-of-toxicity properties that disrupt protein and RNA homeostasis._Autophagy_15 1665–1667. 10.1080/15548627.2019.1633162 [DOI] [PMC free article] [PubMed] [Google Scholar]
54. Hu Y. W., Zhang J., Wu X. M., Cao L., Nie P., Chang M. X. (2018). TANK-binding kinase 1 (TBK1) isoforms negatively regulate type I Interferon Induction by inhibiting TBK1-IRF3 interaction and IRF3 phosphorylation._Front. Immunol._9:84. 10.3389/fimmu.2018.00084 [DOI] [PMC free article] [PubMed] [Google Scholar]
55. Huey E. D., Ferrari R., Moreno J. H., Jensen C., Morris C. M., Potocnik F., et al. (2012). FUS and TDP43 genetic variability in FTD and CBS._Neurobiol. Aging_33 e9–e17. 10.1016/j.neurobiolaging.2011.08.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
56. Ishigaki S., Sobue G. (2018). Importance of functional loss of FUS in FTLD/ALS._Front. Mol. Biosci._5:44. 10.3389/fmolb.2018.00044 [DOI] [PMC free article] [PubMed] [Google Scholar]
57. Jiang J., Zhu Q., Gendron T. F., Saberi S., McAlonis-Downes M., Seelman A., et al. (2016). Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 Is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs._Neuron_90 535–550. 10.1016/j.neuron.2016.04.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
58. Johnson J. O., Mandrioli J., Benatar M., Abramzon Y., Van Deerlin V. M., Trojanowski J. Q., et al. (2010). Exome sequencing reveals VCP mutations as a cause of familial ALS._Neuron_68 857–864. 10.1016/j.neuron.2010.11.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
59. Jovicic A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S. B., et al. (2015). Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS._Nat. Neurosci._18 1226–1229. 10.1038/nn.4085 [DOI] [PMC free article] [PubMed] [Google Scholar]
60. Jung K. T., Oh S. H. (2019). Polyubiquitination of p62/SQSTM1 is a prerequisite for Fas/CD95 aggregation to promote caspase-dependent apoptosis in cadmium-exposed mouse monocyte RAW264.7 cells._Sci. Rep._9:12240. 10.1038/s41598-019-48684-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
61. Kang J., Lim L., Lu Y., Song J. (2019). A unified mechanism for LLPS of ALS/FTLD-causing FUS as well as its modulation by ATP and oligonucleic acids._PLoS Biol._17:e3000327. 10.1371/journal.pbio.3000327 [DOI] [PMC free article] [PubMed] [Google Scholar]
62. Khalfallah Y., Kuta R., Grasmuck C., Prat A., Durham H. D., Vande Velde C. (2018). TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types._Sci. Rep._8:7551. 10.1038/s41598-018-25767-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
63. Kino Y., Washizu C., Kurosawa M., Yamada M., Miyazaki H., Akagi T., et al. (2015). FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis._Acta Neuropathol. Commun._3:24. 10.1186/s40478-015-0202-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
64. Koppers M., Blokhuis A. M., Westeneng H. J., Terpstra M. L., Zundel C. A., Vieira de Sa R., et al. (2015). C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits._Ann. Neurol._78 426–438. 10.1002/ana.24453 [DOI] [PMC free article] [PubMed] [Google Scholar]
65. Kwiatkowski T. J., Jr., Bosco D. A., Leclerc A. L., Tamrazian E., Vanderburg C. R., Russ C., et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis._Science_323 1205–1208. 10.1126/science.1166066 [DOI] [PubMed] [Google Scholar]
66. Kwon J., Han E., Bui C. B., Shin W., Lee J., Lee S., et al. (2012). Assurance of mitochondrial integrity and mammalian longevity by the p62-Keap1-Nrf2-Nqo1 cascade._EMBO Rep._13 150–156. 10.1038/embor.2011.246 [DOI] [PMC free article] [PubMed] [Google Scholar]
67. Lagier-Tourenne C., Polymenidou M., Cleveland D. W. (2010). TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration._Hum. Mol. Genet._19 R46–R64. 10.1093/hmg/ddq137 [DOI] [PMC free article] [PubMed] [Google Scholar]
68. Lamb R., Rohrer J. D., Real R., Lubbe S. J., Waite A. J., Blake D. J., et al. (2019). A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders._Cold Spring Harb. Mol. Case Stud._5:a003913. 10.1101/mcs.a003913 [DOI] [PMC free article] [PubMed] [Google Scholar]
69. Laurin N., Brown J. P., Morissette J., Raymond V. (2002). Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone._Am. J. Hum. Genet._70 1582–1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
70. Li F., Xie X., Wang Y., Liu J., Cheng X., Guo Y., et al. (2016). Structural insights into the interaction and disease mechanism of neurodegenerative disease-associated optineurin and TBK1 proteins._Nat. Commun._7:12708. 10.1038/ncomms12708 [DOI] [PMC free article] [PubMed] [Google Scholar]
71. Ling S. C., Dastidar S. G., Tokunaga S., Ho W. Y., Lim K., Ilieva H., et al. (2019). Overriding FUS autoregulation in mice triggers gain-of-toxic dysfunctions in RNA metabolism and autophagy-lysosome axis._eLife_8:e40811. 10.7554/eLife.40811 [DOI] [PMC free article] [PubMed] [Google Scholar]
72. Ludtmann M. H., Arber C., Bartolome F., de Vicente M., Preza E., Carro E., et al. (2017). Mutations in valosin-containing protein (VCP) decrease ADP/ATP translocation across the mitochondrial membrane and impair energy metabolism in human neurons._J. Biol. Chem._292 8907–8917. 10.1074/jbc.M116.762898 [DOI] [PMC free article] [PubMed] [Google Scholar]
73. Mackenzie I. R., Rademakers R., Neumann M. (2010). TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia._Lancet Neurol._9 995–1007. 10.1016/S1474-4422(10)70195-2 [DOI] [PubMed] [Google Scholar]
74. May S., Hornburg D., Schludi M. H., Arzberger T., Rentzsch K., Schwenk B. M., et al. (2014). C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration._Acta Neuropathol._128 485–503. 10.1007/s00401-014-1329-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
75. Miller R. G., Mitchell J. D., Moore D. H. (2012). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)._Cochrane Database Syst. Rev._3 CD001447. [DOI] [PubMed] [Google Scholar]
76. Mitra J., Guerrero E. N., Hegde P. M., Liachko N. F., Wang H., Vasquez V., et al. (2019). Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects._Proc. Natl. Acad. Sci. U.S.A._116 4696–4705. 10.1073/pnas.1818415116 [DOI] [PMC free article] [PubMed] [Google Scholar]
77. Mitsui S., Otomo A., Nozaki M., Ono S., Sato K., Shirakawa R., et al. (2018). Systemic overexpression of SQSTM1/p62 accelerates disease onset in a SOD1(H46R)-expressing ALS mouse model._Mol. Brain_11:30. 10.1186/s13041-018-0373-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
78. Morton S., Hesson L., Peggie M., Cohen P. (2008). Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma._FEBS Lett._582 997–1002. 10.1016/j.febslet.2008.02.047 [DOI] [PubMed] [Google Scholar]
79. Murthy A. C., Dignon G. L., Kan Y., Zerze G. H., Parekh S. H., Mittal J., et al. (2019). Molecular interactions underlying liquid-liquid phase separation of the FUS low-complexity domain._Nat. Struct. Mol. Biol._26 637–648. 10.1038/s41594-019-0250-x [DOI] [PMC free article] [PubMed] [Google Scholar]
80. Nalbandian A., Khan A. A., Srivastava R., Llewellyn K. J., Tan B., Shukr N., et al. (2017). Activation of the NLRP3 inflammasome is associated with valosin-containing protein myopathy._Inflammation_40 21–41. 10.1007/s10753-016-0449-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
81. Neumann M., Sampathu D. M., Kwong L. K., Truax A. C., Micsenyi M. C., Chou T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis._Science_314 130–133. [DOI] [PubMed] [Google Scholar]
82. Niaki A. G., Sarkar J., Cai X., Rhine K., Vidaurre V., Guy B., et al. (2019). Loss of dynamic RNA interaction and aberrant phase separation induced by two distinct types of ALS/FTD-Linked FUS mutations._Mol. Cell_77:82-94.e4. 10.1016/j.molcel.2019.09.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
83. Ogura T., Wilkinson A. J. (2001). AAA+ superfamily ATPases: common structure–diverse function._Genes Cells_6 575–597. [DOI] [PubMed] [Google Scholar]
84. O’Rourke J. G., Bogdanik L., Muhammad A. K., Gendron T. F., Kim K. J., Austin A., et al. (2015). C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD._Neuron_88 892–901. 10.1016/j.neuron.2015.10.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
85. Park S., Zuber C., Roth J. (2019). Selective autophagy of cytosolic protein aggregates involves ribosome-free rough endoplasmic reticulum._Histochem. Cell Biol._10.1007/s00418-019-01829-w [Epub ahead of print], [DOI] [PubMed] [Google Scholar]
86. Perrone F., Nguyen H. P., Van Mossevelde S., Moisse M., Sieben A., Santens P., et al. (2017). Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients._Neurobiol. Aging._51 e9–e16. 10.1016/j.neurobiolaging.2016.12.008 [DOI] [PubMed] [Google Scholar]
87. Perry A. K., Chow E. K., Goodnough J. B., Yeh W. C., Cheng G. (2004). Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection._J. Exp. Med._199 1651–1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
88. Peters O. M., Cabrera G. T., Tran H., Gendron T. F., McKeon J. E., Metterville J., et al. (2015). Human C9ORF72 hexanucleotide expansion reproduces RNA Foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice._Neuron_88 902–909. 10.1016/j.neuron.2015.11.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
89. Plewa J., Surampalli A., Wencel M., Milad M., Donkervoort S., Caiozzo V. J., et al. (2018). A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene._Neuromuscul. Disord._28 778–786. 10.1016/j.nmd.2018.06.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
90. Ratnavalli E., Brayne C., Dawson K., Hodges J. R. (2002). The prevalence of frontotemporal dementia._Neurology_58 1615–1621. [DOI] [PubMed] [Google Scholar]
91. Rea S. L., Walsh J. P., Layfield R., Ratajczak T., Xu J. (2013). New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget’s disease of bone._Endocr. Rev._34 501–524. 10.1210/er.2012-1034 [DOI] [PubMed] [Google Scholar]
92. Renton A. E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J. R., et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD._Neuron_72 257–268. 10.1016/j.neuron.2011.09.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
93. Roczniak-Ferguson A., Ferguson S. M. (2019). Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis._bioRxiv [Preprint]_10.26508/lsa.20190035 [DOI] [PMC free article] [PubMed] [Google Scholar]
94. Rothstein J. D. (2017). Edaravone: a new drug approved for ALS._Cell_171:725. 10.1016/j.cell.2017.10.011 [DOI] [PubMed] [Google Scholar]
95. Ryzhakov G., Randow F. (2007). SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK._EMBO J._26 3180–3190. [DOI] [PMC free article] [PubMed] [Google Scholar]
96. Saracino D., Clot F., Camuzat A., Anquetil V., Hannequin D., Guyant-Marechal L., et al. (2018). Novel VCP mutations expand the mutational spectrum of frontotemporal dementia._Neurobiol. Aging_72 e11–e14. [DOI] [PubMed] [Google Scholar]
97. Scekic-Zahirovic J., Sendscheid O., El Oussini H., Jambeau M., Sun Y., Mersmann S., et al. (2016). Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss._EMBO J._35 1077–1097. 10.15252/embj.201592559 [DOI] [PMC free article] [PubMed] [Google Scholar]
98. Shang Y., Huang E. J. (2016). Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis._Brain Res._1647 65–78. 10.1016/j.brainres.2016.03.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
99. Shao Q., Liang C., Chang Q., Zhang W., Yang M., Chen J. F. (2019). C9orf72 deficiency promotes motor deficits of a C9ALS/FTD mouse model in a dose-dependent manner._Acta Neuropathol. Commun._7:32. [DOI] [PMC free article] [PubMed] [Google Scholar]
100. Shi Y., Lin S., Staats K. A., Li Y., Chang W. H., Hung S. T., et al. (2018). Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons._Nat. Med._24 313–325. 10.1038/nm.4490 [DOI] [PMC free article] [PubMed] [Google Scholar]
101. Silva P. R., Nieva G. V., Igaz L. M. (2019). Suppression of conditional TDP-43 transgene expression differentially affects early cognitive and social phenotypes in TDP-43 Mice._Front. Genet._10:369. 10.3389/fgene.2019.00369 [DOI] [PMC free article] [PubMed] [Google Scholar]
102. Sreedharan J., Blair I. P., Tripathi V. B., Hu X., Vance C., Rogelj B., et al. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis._Science_319 1668–1672. 10.1126/science.1154584 [DOI] [PMC free article] [PubMed] [Google Scholar]
103. Strong M. J., Volkening K., Hammond R., Yang W., Strong W., Leystra-Lantz C., et al. (2007). TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein._Mol. Cell Neurosci._35 320–327. [DOI] [PubMed] [Google Scholar]
104. Sun D., Wu R., Zheng J., Li P., Yu L. (2018). Polyubiquitin chain-induced p62 phase separation drives autophagic cargo segregation._Cell Res._28 405–415. 10.1038/s41422-018-0017-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
105. Tan R. H., Yang Y., Kim W. S., Dobson-Stone C., Kwok J. B., Kiernan M. C., et al. (2017). Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis._Acta Neuropathol. Commun._5:76. 10.1186/s40478-017-0480-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
106. Taylor J. P., Brown R. H., Jr., Cleveland D. W. (2016). Decoding ALS: from genes to mechanism._Nature_539 197–206. 10.1038/nature20413 [DOI] [PMC free article] [PubMed] [Google Scholar]
107. Teyssou E., Takeda T., Lebon V., Boillee S., Doukoure B., Bataillon G., et al. (2013). Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology._Acta Neuropathol._125 511–522. [DOI] [PubMed] [Google Scholar]
108. Tsai R. M., Boxer A. L. (2014). Treatment of frontotemporal dementia._Curr. Treat. Options Neurol._16:319. 10.1007/s11940-014-0319-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
109. Twomey E. C., Ji Z., Wales T. E., Bodnar N. O., Ficarro S. B., Marto J. A., et al. (2019). Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding._Science_365:1033. 10.1126/science.aax1033 [DOI] [PMC free article] [PubMed] [Google Scholar]
110. Uhlen M., Fagerberg L., Hallstrom B. M., Lindskog C., Oksvold P., Mardinoglu A., et al. (2015). Proteomics. Tissue-based map of the human proteome._Science_347:1260419. 10.1126/science.1260419 [DOI] [PubMed] [Google Scholar]
111. Van Langenhove T., van der Zee J., Sleegers K., Engelborghs S., Vandenberghe R., Gijselinck I., et al. (2010). Genetic contribution of FUS to frontotemporal lobar degeneration._Neurology_74 366–371. 10.1212/WNL.0b013e3181ccc732 [DOI] [PubMed] [Google Scholar]
112. Van Mossevelde S., van der Zee J., Gijselinck I., Engelborghs S., Sieben A., Van Langenhove T., et al. (2016). Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort._Brain_139(Pt 2), 452–467. 10.1093/brain/awv358 [DOI] [PMC free article] [PubMed] [Google Scholar]
113. van Rheenen W., Shatunov A., Dekker A. M., McLaughlin R. L., Diekstra F. P., Pulit S. L., et al. (2016). Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis._Nat. Genet._48 1043–1048. 10.1038/ng.3622 [DOI] [PMC free article] [PubMed] [Google Scholar]
114. Vance C., Rogelj B., Hortobagyi T., De Vos K. J., Nishimura A. L., Sreedharan J., et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6._Science_323 1208–1211. 10.1126/science.1165942 [DOI] [PMC free article] [PubMed] [Google Scholar]
115. Wang R., Yang B., Zhang D. (2011). Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model._Glia_59 946–958. 10.1002/glia.21167 [DOI] [PMC free article] [PubMed] [Google Scholar]
116. Watts G. D., Wymer J., Kovach M. J., Mehta S. G., Mumm S., Darvish D., et al. (2004). Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein._Nat. Genet._36 377–381. [DOI] [PubMed] [Google Scholar]
117. Weidberg H., Elazar Z. (2011). TBK1 mediates crosstalk between the innate immune response and autophagy._Sci. Signal._4:e39. 10.1126/scisignal.2002355 [DOI] [PubMed] [Google Scholar]
118. Weinreich M., Shepheard S. R., Verber N., Wyles M., Heath P. R., Highley J. R., et al. (2019). Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis._Neuropathol. Appl. Neurobiol._10.1111/nan.12578 [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
119. Weishaupt J. H., Hyman T., Dikic I. (2016). Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia._Trends Mol. Med._22 769–783. 10.1016/j.molmed.2016.07.005 [DOI] [PubMed] [Google Scholar]
120. White M. A., Kim E., Duffy A., Adalbert R., Phillips B. U., Peters O. M., et al. (2018a). Publisher Correction: TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD._Nat. Neurosci._21:1138. 10.1038/s41593-018-0160-y [DOI] [PubMed] [Google Scholar]
121. White M. A., Kim E., Duffy A., Adalbert R., Phillips B. U., Peters O. M., et al. (2018b). TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD._Nat. Neurosci._21 552–563. [DOI] [PMC free article] [PubMed] [Google Scholar]
122. Xiao Y., Zhang J., Shu X., Bai L., Xu W., Wang A., et al. (2019). Loss of mitochondrial protein CHCHD10 in skeletal muscle causes neuromuscular junction impairment._Hum. Mol. Genet._10.1093/hmg/ddz154 [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
123. Yang Y., Willis T. L., Button R. W., Strang C. J., Fu Y., Wen X., et al. (2019). Cytoplasmic DAXX drives SQSTM1/p62 phase condensation to activate Nrf2-mediated stress response._Nat. Commun._10:3759. 10.1038/s41467-019-11671-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
124. Zaffagnini G., Savova A., Danieli A., Romanov J., Tremel S., Ebner M., et al. (2018). Phasing out the bad-How SQSTM1/p62 sequesters ubiquitinated proteins for degradation by autophagy._Autophagy_14 1280–1282. 10.1080/15548627.2018.1462079 [DOI] [PMC free article] [PubMed] [Google Scholar]
125. Zhang K., Donnelly C. J., Haeusler A. R., Grima J. C., Machamer J. B., Steinwald P., et al. (2015). The C9orf72 repeat expansion disrupts nucleocytoplasmic transport._Nature_525 56–61. 10.1038/nature14973 [DOI] [PMC free article] [PubMed] [Google Scholar]
126. Zhang Y. J., Gendron T. F., Ebbert M. T. W., O’Raw A. D., Yue M., Jansen-West K., et al. (2018). Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis._Nat. Med._24 1136–1142. 10.1038/s41591-018-0071-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
127. Zhou Z. D., Saw W. T., Tan E. K. (2017). Mitochondrial CHCHD-containing proteins: physiologic functions and link with neurodegenerative diseases._Mol. Neurobiol._54 5534–5546. 10.1007/s12035-016-0099-5 [DOI] [PubMed] [Google Scholar]